UPCC 02423: Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy for relapsed/refractory multiple myeloma
Enrolling By Invitation
99 years and younger
All
Phase
N/A
30 participants needed
1 Location
Brief description of study
Please refer to the protocol, Section 2 (Objectives and Endpoints) Please refer to the protocol, Section 2 (Objectives and Endpoints) Please refer to the protocol, Section 2 (Objectives and Endpoints)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 853124
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
